Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments
Cancer Science · 2024
DOI: 10.1111/cas.16154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Hironori Fukuda und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan. Hauptthemen laut MEDLINE: Tumor Microenvironment, Lung Neoplasms, Adenocarcinoma of Lung, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Overcoming resistance to immune checkpoint inhibitors is an important issue in patients with non‐small‐cell lung cancer (NSCLC). Transcriptome analysis shows that adenocarcinoma can be divided into three molecular subtypes: terminal respiratory unit (TRU), proximal proliferative (PP), and proximal inflammatory (PI), and squamous cell carcinoma (LUSQ) into four. However, the immunological characteristics of these subtypes are not fully understood. In this study, we investigated the immune landscape of NSCLC tissues in molecular subtypes using a multi‐omics dataset, including tumor‐infiltrating leukocytes (TILs) analyzed using flow cytometry, RNA sequences, whole exome sequences, metabolomic analysis, and clinicopathologic findings. In the PI subtype, the number of TILs increased and the immune response in the tumor microenvironment (TME) was activated, as indicated by high levels of tertiary lymphoid structures, and high cytotoxic marker levels. Patient prognosis was worse in the PP subtype than in other adenocarcinoma subtypes. Glucose transporter 1 (GLUT1) expression levels were upregulated and lactate accumulated in the TME of the PP subtype. This could lead to the formation of an immunosuppressive TME, including the inactivation of antigen‐presenting cells. The TRU subtype had low biological malignancy and “cold” tumor‐immune phenotypes. Squamous cell carcinoma (LUSQ) did not show distinct immunological characteristics in its respective subtypes. Elucidation of the immune characteristics of molecular subtypes could lead to the development of personalized immune therapy for lung cancer. Immune checkpoint inhibitors could be an effective treatment for the PI subtype. Glycolysis is a potential target for converting an immunosuppressive TME into an antitumorigenic TME in the PP subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.
- Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
- Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
- Chugai Life Science Park Yokohama, Chugai Pharmaceutical Co. Ltd, Yokohama, Japan.
- Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
- Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
ORCID-Profile: Kosuke Arai, Nobuyoshi Hiraoka, Shigehisa Kitano, Atsushi Ochiai, Kazunori Aoki
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Fukuda, H., Arai, K., Mizuno, H., Nishito, Y., Motoi, N., Arai, Y., Hiraoka, N., Shibata, T., Sonobe, Y., Kayukawa, Y., Hashimoto, E., Takahashi, M., Fujii, E., Maruyama, T., Kuwabara, K., Nishizawa, T., Mizoguchi, Y., Yoshida, Y., Watanabe, S. I., …, & Aoki, K. (2024). Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments. Cancer Science. https://doi.org/10.1111/cas.16154
Vancouver
Fukuda H, Arai K, Mizuno H, Nishito Y, Motoi N, Arai Y, et al. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments. Cancer Science. 2024. doi:10.1111/cas.16154
BibTeX
@article{Fukuda2024,
author = {Fukuda, Hironori and Arai, Kosuke and Mizuno, Hideaki and Nishito, Yukari and Motoi, Noriko and Arai, Yasuhito and Hiraoka, Nobuyoshi and Shibata, Tatsuhiro and Sonobe, Yukiko and Kayukawa, Yoko and Hashimoto, Eri and Takahashi, Mina and Fujii, Etsuko and Maruyama, Toru and Kuwabara, Kenta and Nishizawa, Takashi and Mizoguchi, Yukihiro and Yoshida, Yukihiro and Watanabe, Shun-Ichi and Yamashita, Makiko and Kitano, Shigehisa and Sakamoto, Hiromi and Nagata, Yuki and Mitsumori, Risa and Ozaki, Kouichi and Niida, Shumpei and Kanai, Yae and Hirayama, Akiyoshi and Soga, Tomoyoshi and Tsukada, Keisuke and Yabuki, Nami and Shimada, Mei and Kitazawa, Takehisa and Natori, Osamu and Sawada, Noriaki and Kato, Atsuhiko and Yoshida, Teruhiko and Yasuda, Kazuki and Ochiai, Atsushi and Tsunoda, Hiroyuki and Aoki, Kazunori},
title = {Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16154}
}
EUVIMED